Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Funding callPharmacology and drug development · International

EP PerMed JTC2027 – Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)

The EP PerMed Joint Transnational Call 2027, Cell and Gene Therapy for Personalised Medicine (CGT4PM2027), funds transnational consortia developing and validating innovative cell and gene therapies for personalised medicine, with funding provided by participating national agencies. This guide covers research areas consistent with the call, eligibility and readiness checks, what assessment panels typically value and how to prepare a pre-proposal by 20 January 2027, with invited full proposals due 25 May 2027.

Pubrica InsightsEditorial team, reviewed by a subject specialist
Next deadline
20 January 2027
Last checked
10 November 2026
Funder
European Partnership for Personalised Medicine (EP PerMed)
Sources
1
Apply through the official call

Key dates

Application deadline
20 January 2027
Details last checked
10 November 2026
Apply through the official call

About the call

Funder
European Partnership for Personalised Medicine (EP PerMed)
Country
International
Scheme type
Project grant
Funding
As stated in the call documents
Eligibility
Transnational consortia developing and validating innovative cell and gene therapies for personalised medicine, funded by participating national agencies; invited full proposals due 25 May 2027.
Scope
Pharmacology and drug development

Topics consistent with the call

  • Development of gene therapies tailored to specific patient groups
  • Engineered cell therapies, including CAR-T and other immune cell approaches
  • Patient stratification and biomarkers for cell and gene therapy
  • Preclinical validation and models for personalised cell and gene therapies
  • Manufacturing, quality and scalability of personalised advanced therapies
  • Ethical, regulatory and health economic aspects of personalised therapies

Based on the published scope; the official page sets out the full themes and requirements.

Is your work a fit? Check before you apply

  1. Confirm that the project develops or validates cell or gene therapies for personalised medicine.
  2. Build a transnational consortium that meets the call’s composition rules.
  3. Check that each partner is eligible for funding from its participating national agency.
  4. Review national regulations and budget rules in the official call documents.
  5. Submit a complete, institutionally approved pre-proposal before 20 January 2027.

Why This Funding Call Matters

Cell and gene therapies offer the possibility of treatments designed around an individual’s genetic or cellular profile, but moving them from concept to validated therapy requires expertise and infrastructure that few groups hold alone. Transnational consortia allow complementary partners to combine resources across countries. The EP PerMed call is designed to support such collaborations, helping teams advance personalised advanced therapies towards clinical use within a coordinated European framework.

Who Should Apply

Academic backgrounds

  • Gene therapy
  • Cell therapy and immunotherapy
  • Translational medicine
  • Molecular genetics
  • Regulatory science and health economics

Institutions and sectors

  • Universities and university hospitals
  • Public research organisations
  • Small and medium-sized biotechnology enterprises
  • Patient organisations involved in research

What Reviewers Typically Value

  1. Innovative therapeutic approaches with a clear personalised medicine rationale.
  2. A well-integrated consortium where each partner adds essential expertise.
  3. A realistic path towards validation and clinical translation.
  4. Attention to regulatory, ethical and patient perspectives from the outset.

Ideas You Could Develop

Personalised CAR-T for solid tumoursA consortium developing CAR-T cells targeting patient-specific tumour antigens and validating them in preclinical models.
Gene therapy for a rare inherited disorderA project designing and validating a gene therapy for a defined genetic subgroup of a rare disease.
Biomarkers of response to cell therapyA study identifying biomarkers that predict which patients benefit from an existing cell therapy.

Your Plan to the Deadline

A suggested schedule working back from 20 January 2027. Adjust it to the stage your work has reached.

  1. By 25 Nov 2026

    Read the call documents; confirm eligibility, budget limits, assessment criteria and institutional requirements.

  2. By 9 Dec 2026

    Agree the research question, aims, team and partners; contact your research office.

  3. By 23 Dec 2026

    Draft the case for support, methods, impact and budget.

  4. By 6 Jan 2027

    Obtain internal review, letters of support and institutional sign-off.

  5. By 15 Jan 2027

    Final checks against the funder’s guidance and formatting rules.

  6. By 20 Jan 2027

    Submit through the funder’s system before the deadline.

What you gain

  • Funding for the research, team and resources it needs.
  • Recognition from a competitive, peer-reviewed process.
  • Reviewer feedback that strengthens future applications.
  • A track record for larger grants and fellowships.

What happens after you apply

  1. Eligibility check: the funder confirms the application meets the call rules.
  2. Peer review: external reviewers assess the proposal against the published criteria.
  3. Panel: a committee ranks proposals; some schemes include an interview.
  4. Decision: outcomes are released on the funder’s timetable.
  5. Award: successful applicants agree terms and reporting requirements before starting.

What the Funder Are Looking For

EP PerMed is looking for transnational consortia developing and validating innovative cell and gene therapies for personalised medicine, funded through participating national agencies. Strong proposals typically combine a clear personalised medicine rationale with complementary partners, a feasible translational plan and early attention to regulatory and patient issues. Consortium rules, national eligibility and both deadlines should be confirmed in the official EP PerMed JTC2027 call documents.

Read the official pageThis guide summarises the opportunity. Confirm deadlines, eligibility and requirements on the official page before you plan your work, and record the date you checked it.Open the official page

Expert help

How Pubrica Can Help

Pubrica’s subject specialists can help you prepare a competitive proposal, planned back from the deadline. You remain the author of your work.

Grant writingProposal writing structured to the funder’s guidance and assessment criteria. Literature review and gap analysisThe evidence base and the gap your proposal addresses. Study designStudy design and methods that reviewers can assess. Statistical analysis planSample size and analysis plans for the proposal. Data management planData management and sharing plans to funder requirements. Proposal editingEditing of the full proposal for clarity and consistency.
Go to the official page

FAQs

Questions Researchers Ask

The next published deadline is 20 January 2027. Dates can change, so confirm them on the official page before you plan your work.

The call is described as funding transnational consortia, so single-institution applications are unlikely to be eligible. Check the EP PerMed JTC2027 call documents for the minimum consortium size and country requirements.

Transnational consortia developing and validating innovative cell and gene therapies for personalised medicine, funded by participating national agencies; invited full proposals due 25 May 2027. Confirm the full eligibility rules in the call documents.

Yes. Pubrica’s specialists can review, write, edit and format your proposal. You remain the author and the person responsible for the submission.

Sources

  1. European Partnership for Personalised Medicine (EP PerMed). (2026). EP PerMed JTC2027 – Cell and Gene Therapy for Personalised Medicine (CGT4PM2027). Retrieved 10 November 2026, from https://www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2027_pre-announcement.pdf

How to cite this page

Pubrica Insights. (2026). EP PerMed JTC2027 – Cell and Gene Therapy for Personalised Medicine (CGT4PM2027). Pubrica. https://pubrica.com/insights/calls-and-conferences/ep-permed-jtc2027-cell-and-gene-therapy-for-personalised-medicine-cgt4/

  • EP PerMed
  • Cell and gene therapy
  • Personalised medicine
  • Transnational call
  • Europe

Other Open Funding Calls

Closes 19 November 2026FAPESP Young Investigator Grant for International ResearchersBrazil Closes 24 November 2026MSCA Doctoral Networks 2026 (HORIZON-MSCA-2026-DN-01)International Closes 30 November 2026First in the World Challenge Grants 2026India

All calls, conferences and fundingGrant writing

EP PerMed JTC2027 – Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)Next deadline 20 January 2027

Official page
Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.